| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis |
|
Medicine details |
|
| Medicine name | alemtuzumab (Lemtrada®) |
| Formulation | 12 mg concentrate for solution for infusion |
| Reference number | 342 |
| Indication | Treatment of adult patients with relapsing remitting multiple sclerosis with active disease defined by clinical or imaging features |
| Company | Genzyme Therapeutics |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 31/07/2013 |
| NICE guidance | TA312: Alemtuzumab for treating relapsing‑remitting multiple sclerosis |